Gamma- Glutamylcusteine

Phase 1

Gamma- Glutamylcusteine is one of 5 therapeutic programs targeting Mild Cognitive Impairment (MCI). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Mild Cognitive Impairment (MCI)Recruiting

Mild Cognitive Impairment (MCI)Phase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Mild Cognitive Impairment (MCI)

#DrugCompanyPhaseTrials

Emtriva

Gilead

Phase 1

1 2

KDS2010

NNeuroBiogen Co., Ltd

Phase 2

1 3

Gamma- Glutamylcysteine

PPravat Mandal

Phase 1

1 4

Gamma- Glutamylcusteine

PPravat Mandal

Phase 1

1 5

TAF/FTC

GGöteborg University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Mild Cognitive Impairment (MCI)

NCT07583251

Clinical

Trials by Indication[1]

Mild Cognitive Impairment (MCI)1 trial

Study For Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

Recruiting·PPravat Mandal·Phase 1·NCT07583251·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gamma- Glutamylcusteine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Gamma- Glutamylcusteine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pravat Mandal company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: PPravat Mandal

Gamma- Glutamylcusteine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Mild Cognitive Impairment (MCI)1 trial

References

Drug Info

Quick Facts

Related News